Policy Options to Lower Drug Prices

This comment from Duke-Margolis researchers has been informed by the work of the Duke-Margolis ReVAMP Drug Supply Chain Consortium, which consists of a group of experts in supply chain, manufacturing, regulatory science, national security, and drug shortages from academia, private industry, and additional relevant stakeholder groups. The Consortium’s mission is to generate effective policy solutions that promote a reliable drug supply chain to reduce the frequency and severity of chronic drug shortages. Though the Institute’s work with Consortium members informs this comment, this comment may not represent the views of Consortium members and is not intended to limit the ability of Consortium members to comment independently.

Read the full comment letter.